TSX · MSCL.TO
Satellos Bioscience Inc.
CA$9.60+CA$0.57 (+6.31%)
Satellos Bioscience Inc.’s quoted price sits in the lower half of its reported 52-week range, 49.42% below the high.
Loading market information…
TSX · MDNA.TO · CAD
Stock price, earnings
Quote as of Oct 29, 2026, 07:59 PM UTC. Cached market data; not a live quote.
One-year closing-price history · CAD. Historical prices are not a forecast.
Medicenna Therapeutics Corp.’s quoted price sits in the lower half of its reported 52-week range, 73.03% below the high.
52-week range
Go beyond this overview with deeper company research in PortfolioX. Explore more in the app
BEHIND THE RESULTS
Medicenna Therapeutics Corp.’s next earnings report is currently expected on Nov 12, 2026, with estimated earnings per share of -CA$0.05. The reporting date and estimates may change.
Upcoming dates and analyst estimates may change. Fiscal quarters follow Medicenna Therapeutics Corp.’s reporting calendar.
THE COMPANY BEHIND THE TICKER
Medicenna Therapeutics Corp. is an immunotherapy firm focused on creating and commercializing Superkines and "empowered Superkines" to combat cancer and various other illnesses. Their primary candidate, MDNA55, an interleukin-4 (IL-4) empowered cytokine, has successfully finished Phase IIb trials for recurrent glioblastoma and is also being investigated for other brain and non-brain tumor types in earlier developmental stages. The company's pipeline also includes MDNA11, an improved IL-2 variant designed to stimulate immune responses against cancer; MDNA209, an IL-2 antagonist aimed at autoimmune conditions like multiple sclerosis and graft-versus-host disease; MDNA413, a dual IL-4/IL-13 antagonist for use in cancer immunotherapy; and MDNA132, an IL-13 Superkine targeting solid tumors. Furthermore, Medicenna utilizes its BiSKITs platform to engineer bespoke Superkines by joining them with proteins, antibodies, cytokines, or other Superkines. The company's main office is located in Toronto, Canada.
Latest available per-share figures in CAD. The payout ratio compares dividends with earnings.
About this data · PortfolioX market data, also available in the mobile app. Prices are displayed in the listing currency; dividend amounts use the currency shown in that section. Data availability and update times vary.
Page generated Oct 30, 2026, 08:46 AM UTC. Quotes retain their own timestamp above. Missing values appear as a dash. This page is for information only, not personalized investment advice.
| Jun 26, 2025 |
| CA$0.02+133.33% vs estimate |
| CA$0.00-100.0% vs estimate |
| Q3 2025 | Feb 13, 2025 | -CA$0.07-10.53% vs estimate | CA$0.00-100.0% vs estimate |
|---|
| Q2 2025 | Nov 14, 2024 | -CA$0.05+16.67% vs estimate | CA$0.00-100.0% vs estimate |
|---|
THE ANALYST VIEW
1 ratings in the current snapshot. Strong buy and strong sell are grouped with buy and sell.
HOW THE BUSINESS IS PERFORMING
Statement amounts use the company’s reporting currency and are not converted to the stock’s listing currency. K = thousand, M = million, B = billion, T = trillion. Cash-flow figures are matched by fiscal year; missing figures appear as a dash.
PUT THE NUMBERS IN CONTEXT
Current metrics alongside available historical medians. A lower multiple or higher margin alone does not establish whether a stock is a good investment.
KEEP COMPARING
CA$9.60+CA$0.57 (+6.31%)
Satellos Bioscience Inc.’s quoted price sits in the lower half of its reported 52-week range, 49.42% below the high.
CA$5.04+CA$0.09 (+1.82%)
Medexus Pharmaceuticals Inc.’s quoted price sits in the upper half of its reported 52-week range, 8.36% below the high.
CA$4.46-CA$0.04 (-0.89%)
Covalon Technologies Ltd.’s quoted price sits in the upper half of its reported 52-week range, 2.83% below the high.
CA$0.55-CA$0.01 (-1.79%)
Zentek Ltd.’s quoted price sits in the lower half of its reported 52-week range, 63.33% below the high.
CA$0.81-CA$0.01 (-1.22%)
Arch Biopartners Inc.’s quoted price sits in the lower half of its reported 52-week range, 44.14% below the high.
CA$0.11CA$0.00 (0.0%)
Sernova Corp.’s quoted price sits in the lower half of its reported 52-week range, 45.0% below the high.
CA$0.29CA$0.00 (0.0%)
BioNxt Solutions Inc.’s quoted price sits in the lower half of its reported 52-week range, 66.86% below the high.
CA$0.12CA$0.00 (0.0%)
Planet 13 Holdings Inc.’s quoted price sits in the lower half of its reported 52-week range, 79.09% below the high.
